Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease

American Journal of Gastroenterology

Volumn 104, Issue 11, 2009, Pages 2768-2773

  Toedter, Gary P ^a   Blank, Marion ^a   Lang, Yinghua ^a   Chen, Dion ^a   Sandborn, William J ^b   De Villiers, Willem J S ^c  

^a CENTOCOR INC   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; IMMUNOMODULATING AGENT; INFLIXIMAB; MESALAZINE; PLACEBO; USTEKINUMAB;

ADULT; ARTICLE; CLINICAL TRIAL; COLON; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; CROSSOVER PROCEDURE; HUMAN; ILEUM; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; C-REACTIVE PROTEIN; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION MEDIATORS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROBABILITY; RECURRENCE; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 72049124819     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.454     Document Type: Article

References (21)

1. Baumgart DC , Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007;369:1627-1640 (Pubitemid 46722636)
2. Hanauer SB, Feagan BG , Lichtenstein ein GR et al . Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-1549 (Pubitemid 34621118)
3. Hanauer SB , Sandborn WJ , Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC I trial. Gastroenterology 2006;130:323-333 (Pubitemid 43202032)
4. Rutgeerts P , Feagan BG , Lichtenstein GR et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402-413 (Pubitemid 38182297)
5. Sandborn WJ , Rutgeerts P , Ennis R et al. Adalimumab induction therapy for Crohn's disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146:829-838 (Pubitemid 351650483)
6. Schreiber S , Khaliq-Kareemi M , Lawrance IC et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239-250 (Pubitemid 47080388)
7. Sandborn WJ , Feagan BG , Stoinov S et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-238 (Pubitemid 47080387)
8. Sandborn WJ , Feagan BG , Fedorak RN et al. A randomized trial of ustekinumab a human interleukin-12/23 monoclonal antibody, in patients with moderate to severe Crohn's disease. Gastroenterology 2008;135:1130-1141
9. Pepys MB , Hirschfi eld GM. C-reactive protein: a critical update. J . Clin . Invest 2003;111:1805-1812
10. Vermeire S , Van Assche G , Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Infl amm Bowel Dis 2004;10:661-665 (Pubitemid 39276479)
11. Solem CA , Loft us EV Jr , Tremaine WJ et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:707-712 (Pubitemid 41271173)
12. Jones J , Loft us EV Jr , Panaccione R et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008;6:1218-1224
13. Koelewijn CL , Schwartz MP , Samsom M et al. C-reactive protein levels during a relapse of Crohn's disease are associated with the clinical course of the disease. World J Gastroenterol 2008;14:85-89 (Pubitemid 351314332)
14. Schreiber S , Rutgeerts P , Fedorak RN et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterol 2005;129:807-818 (Pubitemid 41242673)
15. Kasper LH , Everitt D , Leist TP et al. A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis. Curr Med Res Opin 2006;22:1671-1678 (Pubitemid 44449223)
16. Rodgers AD , Cummins AG. CRP correlates with clinical score in ulcerative colitis but not in Crohn's disease. Dig Dis Sci 2007;52:2063-2068 (Pubitemid 47246515)
17. Sandborn WJ , Colombel JF , Enns R. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353:1912-1925 (Pubitemid 41565956)
18. Targan SR , Feagan BG , Fedorak RN et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology 2007;132:1672-1683 (Pubitemid 46695722)
19. Florin THJ , Paterson EWJ , Fowler EV et al. Clinically active Crohn's disease in the presence of a low C-reactive protein. Scand J Gastroenterology 2006;41:306-311 (Pubitemid 43311042)
20. Sipponen T , Kärkkäinen P , Savilahti E et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Th er 2008;28:1221-1229
21. Schoepfer AM , Trummler M , Seeholzer P et al. Discriminating IBD from IBS: comparison of the test performance of fecal makers, blood leukocytes, CRP, and IBD antibodies. Infl amm Bowel Dis 2008;14:32-39 (Pubitemid 351196866)